VivoSeq
Other

Erectile Dysfunction

116

Pipeline Programs↗

18

Active Trials↗

51

Companies Involved↗

Erectile Dysfunction is a highly competitive landscape with 116 programs across 51 companies. The most active players are Rohto Pharmaceutical Co., Ltd., Revance Therapeutics, Inc., Initiator Pharma. 32 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

32/100

Mech. Concentration

10/100

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rohto Pharmaceutical Co., Ltd.

1 program

Phase 1R

Revance Therapeutics, Inc.

1 program

Phase 1I

Initiator Pharma

2 programs

Phase 2D

Dong-A Pharmaceutical Co., Ltd.

1 program

Phase 2Q

QuatRx Pharmaceuticals Company

1 program

Phase 2R

Rexahn Pharmaceuticals, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical25

Verapamil

Val Adams

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Sotorasib

Amgen

Osimertinib

AstraZeneca

Phase 14

Alcohol

Astellas

Mesenchymal Stem Cell

Rohto Pharmaceutical Co., Ltd.

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Tadalafil /sildenafil

Assiut University

Phase 238

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Mirabegron

Astellas

Pentoxifylline

Validus Pharmaceuticals

UK-369,003

Pfizer

Phase 317

Platelet Rich Plasma

Zagazig University

LCZ696

Novartis

Enalapril

Bausch Health Americas, Inc.

Simvastatin

Organon and Co

Dapoxetine

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved32

Rifampin

Sanofi

Ciprofloxacin

Bayer

Vardenafil

Bayer

Sildenafil

Viatris Specialty LLC

Avanafil

VIVUS LLC

Analysis

Modality Breakdown

90%

Small molecule

127 of 141 classified programs — the dominant modality here.

10%ALL OTHERSCell therapy118%Monoclonal antibody32%

Small molecule leads; the ring shows all 141 classified programs, each share of the total. Modality classified for 97% of 151 pipeline programs.

Analysis

Trial Status

197

clinical trials

Completed142 · 72%
Unknown status26 · 13%
Recruiting10 · 5%
Terminated6 · 3%
Not yet recruiting5 · 3%
Withdrawn5 · 3%
Other3 · 2%

Clinical Trials

Trial Activity

197 trials

Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction
Recruiting·UUniversity of Manitoba·Phase 1·NCT06264635·60 enrolled
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes
Recruiting·UUniversity Medical Centre Ljubljana·Phase 3·NCT06520839·90 enrolled
PRP Exosomes Therapy for Erectile Dysfunction
Recruiting·IInstitute for the Study of Urological Diseases, Greece·Phase 2·NCT07124871·30 enrolled
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06532149·80 enrolled
Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction
Recruiting·—·Phase 2/3·NCT07480161·90 enrolled
Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients
Recruiting·MMansoura University·Phase 4·NCT07391579·500 enrolled
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate
Recruiting·MMansoura University·Phase 2/3·NCT05955001·110 enrolled
Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction
Recruiting·—·Phase 2/3·NCT06583590·32 enrolled
A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
Recruiting·AAzienda USL Reggio Emilia - IRCCS·N/A·NCT07061145·350 enrolled
A Randomized Clinical Trial to Assess Safety and Efficacy of Allogeneic Adipose-derived Mesenchymal Stem Cells in Promoting the Recovery of Erectile Function Post Radical Retropubic Prostatectomy of Localized Prostate Cancer
Recruiting·TThe Methodist Hospital Research Institute·Preclinical·NCT07048314·40 enrolled
Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction
Active, not recruiting·—·Phase 3·NCT06942988·34 enrolled
Satisfaction of Patients With Erectile Dysfunction With the Use of Sildenafil Oral Suspension Compared to Orodispersible Tablets
Active, not recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·N/A·NCT07676617·55 enrolled
Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
Not yet recruiting·BBeijing Inno Medicine Co., Ltd.·Phase 2·NCT07311330·40 enrolled
Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction
Not yet recruiting·AAspargo Labs, Inc·Phase 2·NCT07231185·200 enrolled
Clinical Trial Investigating the Effect of Exosomes as a Complementary Treatment in Severe to Moderate Erectile Dysfunction
Not yet recruiting·LLabbafinejad Medical Center·Phase 2·NCT07319533·70 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)